Rituximab Administration to Treat Nephrotic Syndrome in Children: 2-Year Follow-Up
RTX was tolerated well, and proved highly effective as a steroid-sparing agent, offering potential in terms of stopping relapses and minimizing steroid-related side effects. It also demonstrated efficacy in slowing progression in SRNS, indicating potential for use in ACR reduction and renal function restoration, but requires careful use given potential severe allergic reactions and infectious complications. Further studies should focus on long-term cost-effectiveness and deferred side effects.
Authors
- Iryna Zavalna (ORCID: https://orcid.org/0000-0002-5541-7351)
- Lutz T. Weber (ORCID: https://orcid.org/0000-0003-4116-598X)
- Elena Levtchenko (ORCID: https://orcid.org/0000-0002-8352-7312)
- Mariia Ivanova (ORCID: https://orcid.org/0000-0002-7636-1000)
- Yelizaveta Lagodych (ORCID: https://orcid.org/0000-0002-1045-4482)
- Л.І. Вакуленко (ORCID: https://orcid.org/0000-0003-3823-6134)
- Д.Д. Іванов (ORCID: https://orcid.org/0000-0003-2609-0051)
- Ninel Boiko (ORCID: https://orcid.org/0009-0006-8828-7385)
Institutions
- Emma Kinderziekenhuis (NL)
- Rivne State University of Humanities (UA)
- European Institute of Oncology (IT)
- Bogomolets National Medical University (UA)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-11-13
- DOI
- https://doi.org/10.3390/biomedicines12112600
- Citations
- 6
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.04